A comparative analysis of kratom exposure cases in Thailand and the United States from 2010-2017

References

• Hassan Z, Muzaimi M, Navaratnam V, Yusoff NH, Suhaimi FW, Vadivelu R, Vicknasingam BK, Amato D, von Hörsten S, Ismail NIW, et al. From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction. Neurosci Biobehav Rev. 2013;37:138–51.
   PubMed Web of Science ®Google Scholar
• Cinosi E, Martinotti G, Simonato P, Singh D, Demetrovics Z, Roman-Urrestarazu A, Bersani FS, Vicknasingam B, Piazzon G, Li J-H, et al. Following “the Roots” of Kratom (Mitragyna speciosa): the evolution of an enhancer from a traditional use to increase work and productivity in Southeast Asia to a recreational psychoactive drug in western countries. Biomed Res Int. 2015;2015:968786.
   PubMed Web of Science ®Google Scholar
• Tanguay P. Kratom in Thailand: decriminalisation and community control? Int Drug Policy Consortium. [Internet]. 2011 February 21, 2020. Available from: http://www.druglawreform.info/images/stories/documents/dlr13.pdf
   Google Scholar
• Jansen KL, Prast CJ. Ethnopharmacology of kratom and the Mitragyna alkaloids. J Ethnopharmacol. 1988;23:115–19. doi:10.1016/0378-8741(88)90121-3.
   PubMed Web of Science ®Google Scholar
• Swogger MT, Walsh Z. Kratom use and mental health: A systematic review. Drug Alcohol Depend. 2018;183:134–40. doi:10.1016/j.drugalcdep.2017.10.012.
   PubMed Web of Science ®Google Scholar
• Anwar ML, Schier R. J. notes from the field. Kratom (Mitragyna speciosa) exposures reported to poison centers — United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65:748–49. doi:10.15585/mmwr.mm6529a4.
   PubMed Web of Science ®Google Scholar
• Kruegel AC, Grundmann O. The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse. Neuropharmacology. 2018;134:108–20. doi:10.1016/j.neuropharm.2017.08.026.
   PubMed Web of Science ®Google Scholar
• Post S, Spiller HA, Chounthirath T, Smith GA. Kratom exposures reported to United States poison control centers: 2011-2017. Clin Toxicol (Phila). 2019;57:847–54. doi:10.1080/15563650.2019.1569236.
   PubMed Web of Science ®Google Scholar
• Henningfield JE, Fant RV, Wang DW. The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research. Psychopharmacology (Berl). 2018;235:573–89. doi:10.1007/s00213-017-4813-4.
   PubMed Web of Science ®Google Scholar
• Statement from FDA Commissioner Scott Gottlieb, M.D. on FDA advisory about deadly risks associated with kratom [press release]. Maryland, United States: U.S. Food and Drug Administration, 2017.
   Google Scholar
• Statement from FDA Commissioner Scott Gottlieb, M.D. on the agency’s scientific evidence on the presence of opioid compounds in kratom, underscoring its potential for abuse [press release]. Maryland, United States: US Food and Drug Administration, February 06 2018.
   Google Scholar
• Fluyau D, Revadigar N. Biochemical benefits, diagnosis, and clinical risks evaluation of kratom. Front Psychiatry. 2017;8:62. doi:10.3389/fpsyt.2017.00062.
   PubMed Web of Science ®Google Scholar
• Griffin OH, Webb ME. The scheduling of kratom and selective use of data. J Psychoactive Drugs. 2018;50:114–20. doi:10.1080/02791072.2017.1371363.
   PubMed Web of Science ®Google Scholar
• Boyer EW, Babu KM, Adkins JE, McCurdy CR, Halpern JH. Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth). Addiction. 2008;103:1048–50. doi:10.1111/j.1360-0443.2008.02209.x.
   PubMed Web of Science ®Google Scholar
• Tungtananuwat W, Lawanprasert S. Fatal 4x100: home-made kratom juice cocktail. J Health Res. 2010;24:43–47.
   Google Scholar
• Prozialeck WC, Jivan JK, Andurkar SV. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. J Am Osteopath Assoc. 2012;112:792–99.
   PubMedGoogle Scholar
• Warner ML, Kaufman NC, Grundmann O. The pharmacology and toxicology of kratom: from traditional herb to drug of abuse. Int J Legal Med. 2016;130:127–38. doi:10.1007/s00414-015-1279-y.
   PubMed Web of Science ®Google Scholar
• White CM. Pharmacologic and clinical assessment of kratom. Am J Health Syst Pharm. 2018;75:261–67. doi:10.2146/ajhp161035.
   PubMed Web of Science ®Google Scholar
• Raffa RB, Pergolizzi JV, Taylor R, Ossipov MH, Group NR. Nature’s first “atypical opioids”: kratom and mitragynines. J Clin Pharm Ther. 2018;43:437–41. doi:10.1111/jcpt.12676.
   PubMed Web of Science ®Google Scholar
• Gummin DD, Mowry JB, Spyker DA, Brooks DE, Fraser MO, Banner W. 2016 annual report of the american association of poison control centers’ national poison data system (NPDS): 34th annual report. Clin Toxicol (Phila). 2017;55:1072–252. doi:10.1080/15563650.2017.1388087.
   PubMed Web of Science ®Google Scholar
• Gummin DD, Mowry JB, Spyker DA, Brooks DE, Beuhler MC, Rivers LJ, Hashem HA, Ryan ML. 2018 annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 36th annual report. Clin Toxicol (Phila). 2019;57:1220–413.
   Web of Science ®Google Scholar
• Singh D, Muller CP, Vicknasingam BK. Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug Alcohol Depend. 2014;139:132–37. doi:10.1016/j.drugalcdep.2014.03.017.
   PubMed Web of Science ®Google Scholar
• Population, total: The World Bank; 2019 [cited 2019 April 24]. Available from: https://data.worldbank.org/indicator/SP.POP.TOTL.
   Google Scholar
• Singh D, Narayanan S, Grundmann O, Dzulkapli EB, Vicknasingam B. Effects of kratom (Mitragyna Speciosa Korth.) Use in regular users. Subst Use Misuse. 2019;52:1–6.
   Google Scholar
• Lowry JA, Brown JT. Significance of the imidazoline receptors in toxicology. Clin Toxicol (Phila). 2014;52:454–69. doi:10.3109/15563650.2014.898770.
   PubMed Web of Science ®Google Scholar
• Horie S, Koyama F, Takayama H, Ishikawa H, Aimi N, Ponglux D, Matsumoto K, Murayama T. Indole Alkaloids of a Thai medicinal herb, mitragyna speciosa, that has opioid agonistic effect in guinea-pig ileum. Planta Med. 2005;71:231–36.
   PubMed Web of Science ®Google Scholar
• Kruegel AC, Gassaway MM, Kapoor A, Varadi A, Majumdar S, Filizola M, Javitch JA, Sames D. Synthetic and receptor signaling explorations of the mitragyna alkaloids: mitragynine as an atypical molecular framework for opioid receptor modulators. J Am Chem Soc. 2016;138:6754–64.
   PubMed Web of Science ®Google Scholar
• Kruegel AC, Uprety R, Grinnell SG, Langreck C, Pekarskaya EA, Le Rouzic V, Ansonoff M, Gassaway MM, Pintar JE, Pasternak GW, et al. 7-hydroxymitragynine is an active metabolite of mitragynine and a key mediator of its analgesic effects. ACS Central Science, 2019;5:992–1001.
   Google Scholar
• Osborne CS, Overstreet AN, Rockey DC, Schreiner AD. Drug-induced liver injury caused by kratom use as an alternative pain treatment amid an ongoing opioid epidemic. J Investig Med High Impact Case Rep. 2019;7:2324709619826167.
   Web of Science ®Google Scholar
• Griffiths CL, Gandhi N, Olin JL. Possible kratom-induced hepatomegaly: A case report. J Am Pharm Assoc (2003). 2018;58:561–63. doi:10.1016/j.japh.2018.05.006.
   PubMed Web of Science ®Google Scholar
• Dorman C, Wong M, Khan A. Cholestatic hepatitis from prolonged kratom use: A case report. Hepatology. 2015;61:1086–87. doi:10.1002/hep.27612.
   PubMed Web of Science ®Google Scholar
• Kapp FG, Maurer HH, Auwarter V, Winkelmann M, Hermanns-Clausen M. Intrahepatic cholestasis following abuse of powdered kratom (Mitragyna speciosa). J Med Toxicol. 2011;7:227–31. doi:10.1007/s13181-011-0155-5.
   PubMedGoogle Scholar
• Tatum WO, Hasan TF, Coonan EE, Smelick CP. Recurrent seizures from chronic kratom use, an atypical herbal opioid. Epilepsy Behav Case Rep. 2018;10:18–20. doi:10.1016/j.ebcr.2018.04.002.
   PubMed Web of Science ®Google Scholar
• Gershman K, Timm K, Frank M, Lampi L, Melamed J, Gerona R, Monte AA. Deaths in Colorado attributed to kratom. N Engl J Med. 2019;380:97–98.
   PubMed Web of Science ®Google Scholar
• Kronstrand R, Roman M, Thelander G, Eriksson A. Unintentional fatal intoxications with mitragynine and O-desmethyltramadol from the herbal blend Krypton. J Anal Toxicol. 2011;35:242–47. doi:10.1093/anatox/35.4.242.
   PubMed Web of Science ®Google Scholar
• McIntyre IM, Trochta A, Stolberg S, Campman SC. Mitragynine ‘Kratom’ related fatality: a case report with postmortem concentrations. J Anal Toxicol. 2015;39:152–55. doi:10.1093/jat/bku137.
   PubMed Web of Science ®Google Scholar
• Lydecker AG, Sharma A, McCurdy CR, Avery BA, Babu KM, Boyer EW. Suspected adulteration of commercial kratom products with 7-hydroxymitragynine. J Med Toxicol. 2016;12:341–49. doi:10.1007/s13181-016-0588-y.
   PubMed Web of Science ®Google Scholar
• Singh D, Narayanan S, Vicknasingam B. Traditional and non-traditional uses of Mitragynine (Kratom): A survey of the literature. Brain Res Bull. 2016;126:41–46. doi:10.1016/j.brainresbull.2016.05.004.
   PubMed Web of Science ®Google Scholar
• Suhaimi FW, Yusoff NH, Hassan R, Mansor SM, Navaratnam V, Muller CP,  Hassan Z. Neurobiology of Kratom and its main alkaloid mitragynine. Brain Res Bull. 2016;126:29–40.
   PubMed Web of Science ®Google Scholar
• White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction. 1999;94:961–72. doi:10.1046/j.1360-0443.1999.9479612.x.
   PubMed Web of Science ®Google Scholar
• Neerman MF, Frost RE, Deking J. A drug fatality involving Kratom. J Forensic Sci. 2013;58 Suppl 1:S278–9. doi:10.1111/1556-4029.12009.
   PubMed Web of Science ®Google Scholar
• Corkery JM, Streete P, Claridge H, Goodair C, Papanti D, Orsolini L, Schifano F, Sikka K, Körber S, Hendricks A. Characteristics of deaths associated with kratom use. J Psychopharmacol. 2019;33:1102–23.
   PubMed Web of Science ®Google Scholar
• Holler JM, Vorce SP, McDonough-Bender PC, Magluilo J Jr., Solomon CJ, Levine B. A drug toxicity death involving propylhexedrine and mitragynine. J Anal Toxicol. 2011;35:54–59. doi:10.1093/anatox/35.1.54.
   PubMed Web of Science ®Google Scholar
• Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature. 2006;440:463–69. doi:10.1038/nature04710.
   PubMed Web of Science ®Google Scholar
• Lu J, Wei H, Wu J, Jamil MF, Tan ML, Adenan MI, Wong P, Shim W. Evaluation of the cardiotoxicity of mitragynine and its analogues using human induced pluripotent stem cell-derived cardiomyocytes. PLoS One. 2014;9:e115648.
   PubMed Web of Science ®Google Scholar
• Tay YL, Teah YF, Chong YM, Jamil MFA, Kollert S, Adenan MI, Wahab HA, Döring F, Wischmeyer E, Tan ML. Mitragynine and its potential blocking effects on specific cardiac potassium channels. Toxicol Appl Pharmacol. 2016;305:22–39.
   PubMed Web of Science ®Google Scholar
• Karinen R, Fosen JT, Rogde S, Vindenes V. An accidental poisoning with mitragynine. Forensic Sci Int. 2014;245:e29–32. doi:10.1016/j.forsciint.2014.10.025.
   PubMed Web of Science ®Google Scholar
• Bernard S, Neville KA, Nguyen AT, Flockhart DA. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. Population: clinical implications. Oncologist. 2006;11:126–35. doi:10.1634/theoncologist.11-2-126.
   PubMed Web of Science ®Google Scholar
• Kong WM, Chik Z, Ramachandra M, Subramaniam U, Aziddin RER, Mohamed Z. Evaluation of the effects of mitragyna speciosa alkaloid extract on cytochrome P450 enzymes using a high throughput assay. Molecules. 2011;16:7344–56. doi:10.3390/molecules16097344.
   PubMed Web of Science ®Google Scholar
• Williams AR, Santaella-Tenorio J, Mauro CM, Levin FR, Martins SS. Loose regulation of medical marijuana programs associated with higher rates of adult marijuana use but not cannabis use disorder. Addiction. 2017;112:1985–91. doi:10.1111/add.13904.
   PubMed Web of Science ®Google Scholar